International Agreement Reached on New Standard for the Evaluation of MRI Scans for Prostate Cancer
By MedImaging International staff writers Posted on 19 Oct 2015 |
The European Association of Urology (EAU; Arnhem, The Netherlands) has published new standards for the acquisition and reporting of Magnetic Resonance Imaging (MRI) scans to confirm a diagnosis of prostate cancer.
The Prostate Imaging and Reporting and Data System (PI-RADS) system standard was agreed between international radiological bodies and was published in the European Association of Urology’s peer-reviewed journal, European Urology. The standard enables radiologists to identify up to 13% more deadly prostate tumors, and could reduce over-diagnosis of insignificant cancers by nearly 89% compared to current procedures. Nearly 80% of men in Europe have a microscopic cancer at age 80, and nearly 50% at age 55.
A new MRI imaging technique, called multiparametric prostate Magnetic Resonance Imaging (mpMRI) has been in use and refined in the past few decades, but image acquisition and reporting guidelines are also essential for identifying prostate cancer. A previous version of the PI-RADS system standard already improved the diagnosis of intermediate- to high-grade cancers in clinical trials. The new version, PI-RADS version 2 updates, provides detailed instructions, and simplifies the acquisition, interpretation, and reporting of mpMRI scans.
Many studies have confirmed that mpMRI can prevent unnecessary biopsies, and improves the ability of a radiologist to identify clinically significant cancers when biopsies are made. MRI-targeted biopsies using mpMRI have been shown to provide better results than current ultrasound guided biopsy protocols.
Prof. Hendrik Van Poppel, University of Leuven, Belgium, from the European Association of Urology, said, "PSA screening decreases prostate cancer mortality but exposes to over-diagnosis and over-treatment. mpMRI will not only simplify this screening, it will also play an important role in the follow-up of patients under active surveillance. It should be the first exam a patient at risk of significant prostate cancer should have. As for the costs of mpMRI, these should be weighed against the saving of costs of unnecessary biopsies, coping with complications and possible unnecessary treatments".
Related Links:
European Association of Urology
The Prostate Imaging and Reporting and Data System (PI-RADS) system standard was agreed between international radiological bodies and was published in the European Association of Urology’s peer-reviewed journal, European Urology. The standard enables radiologists to identify up to 13% more deadly prostate tumors, and could reduce over-diagnosis of insignificant cancers by nearly 89% compared to current procedures. Nearly 80% of men in Europe have a microscopic cancer at age 80, and nearly 50% at age 55.
A new MRI imaging technique, called multiparametric prostate Magnetic Resonance Imaging (mpMRI) has been in use and refined in the past few decades, but image acquisition and reporting guidelines are also essential for identifying prostate cancer. A previous version of the PI-RADS system standard already improved the diagnosis of intermediate- to high-grade cancers in clinical trials. The new version, PI-RADS version 2 updates, provides detailed instructions, and simplifies the acquisition, interpretation, and reporting of mpMRI scans.
Many studies have confirmed that mpMRI can prevent unnecessary biopsies, and improves the ability of a radiologist to identify clinically significant cancers when biopsies are made. MRI-targeted biopsies using mpMRI have been shown to provide better results than current ultrasound guided biopsy protocols.
Prof. Hendrik Van Poppel, University of Leuven, Belgium, from the European Association of Urology, said, "PSA screening decreases prostate cancer mortality but exposes to over-diagnosis and over-treatment. mpMRI will not only simplify this screening, it will also play an important role in the follow-up of patients under active surveillance. It should be the first exam a patient at risk of significant prostate cancer should have. As for the costs of mpMRI, these should be weighed against the saving of costs of unnecessary biopsies, coping with complications and possible unnecessary treatments".
Related Links:
European Association of Urology
Latest MRI News
- Groundbreaking AI-Powered Software Significantly Enhances Brain MRI
- MRI Predicts Patient Outcomes and Tumor Recurrence in Rectal Cancer Patients
- Portable MRI System Dramatically Cuts Time-To-Scan vs. Conventional MRI in Stroke Patients
- Novel Model Identifies Focal Cortical Dysplasia Lesion from MRI Scans
- AI-Enhanced MRI Improves Diagnosis of Brain Disorders
- New Cardiac MRI Strategy Guides Ablation Procedures for Complex Tachycardias
- AI Model Achieves Clinical Expert Level Accuracy in Analyzing Complex MRIs and 3D Medical Scans
- MRI Provides Early Warning System for Glioblastoma Growth
- AI Algorithm Analyzes MRI Scans to Determine Best Rectal Cancer Treatment Strategy
- AI Software Uses MRI Scans to Automatically Segment Key Brain Structures for Improved Radiation Therapy Planning
- AI Software Analyzes Neuroimaging Data and Patient Information to Diagnose 10 Types of Dementia
- Metamaterials to Make MRI Scans Faster, Cheaper, and More Accurate
- Deep Learning Enables Accurate, Automated Quality Control Image Assessment for Liver MR Elastography
- Deep Learning-Based AI for Prostate MRI Helps Improve Risk Assessment and Avoid Unnecessary Biopsies
- Breakthrough Heart MRI Technique Accurately Predicts Heart Failure Risk in General Population
- MRI Could Help Doctors Predict More Aggressive Prostate Cancer in Patients